CN116194483A - 使用抗cd73抗体的癌症治疗方法 - Google Patents

使用抗cd73抗体的癌症治疗方法 Download PDF

Info

Publication number
CN116194483A
CN116194483A CN202180055645.3A CN202180055645A CN116194483A CN 116194483 A CN116194483 A CN 116194483A CN 202180055645 A CN202180055645 A CN 202180055645A CN 116194483 A CN116194483 A CN 116194483A
Authority
CN
China
Prior art keywords
antibody
ser
protein
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180055645.3A
Other languages
English (en)
Chinese (zh)
Inventor
L•高蒂尔
C•帕图雷
I•普罗特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN116194483A publication Critical patent/CN116194483A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180055645.3A 2020-08-13 2021-08-06 使用抗cd73抗体的癌症治疗方法 Pending CN116194483A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063065085P 2020-08-13 2020-08-13
US63/065,085 2020-08-13
PCT/EP2021/072020 WO2022033978A2 (en) 2020-08-13 2021-08-06 Cancer treatment methods using anti-cd73 antibodies

Publications (1)

Publication Number Publication Date
CN116194483A true CN116194483A (zh) 2023-05-30

Family

ID=77595505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180055645.3A Pending CN116194483A (zh) 2020-08-13 2021-08-06 使用抗cd73抗体的癌症治疗方法

Country Status (6)

Country Link
US (1) US20240270865A1 (cg-RX-API-DMAC10.html)
EP (1) EP4196500A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023537115A (cg-RX-API-DMAC10.html)
KR (1) KR20230050378A (cg-RX-API-DMAC10.html)
CN (1) CN116194483A (cg-RX-API-DMAC10.html)
WO (1) WO2022033978A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
WO2025162964A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493563B2 (en) * 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
JP2017517499A (ja) * 2014-04-25 2017-06-29 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 脳中の転移乳癌および他の癌を処置するための方法および組成物
US20180030144A1 (en) * 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
US20200024357A1 (en) * 2018-06-18 2020-01-23 Innate Pharma Compositions and methods for treating cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
WO2016055609A1 (en) * 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
EP3259288B1 (en) 2015-02-20 2026-07-22 Innate Pharma Cd73 blockade
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
US20200172628A1 (en) * 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
WO2020041404A1 (en) * 2018-08-23 2020-02-27 Macrogenics, Inc. Pd-l1-binding molecules and use of the same for the treatment of disease
KR20220002959A (ko) * 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493563B2 (en) * 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
JP2017517499A (ja) * 2014-04-25 2017-06-29 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 脳中の転移乳癌および他の癌を処置するための方法および組成物
US20180030144A1 (en) * 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
US20200024357A1 (en) * 2018-06-18 2020-01-23 Innate Pharma Compositions and methods for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKIL HAMMAMI: "Targeting the adenosine pathway for cancer immunotherapy", SEMINARS IN IMMUNOLOGY, no. 42, 30 April 2019 (2019-04-30), pages 1 - 7 *
MARTIN TURCOTTE: "CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy", CANCER RESEARCH, vol. 77, no. 20, 15 October 2017 (2017-10-15), pages 1 - 12 *

Also Published As

Publication number Publication date
US20240270865A1 (en) 2024-08-15
KR20230050378A (ko) 2023-04-14
EP4196500A2 (en) 2023-06-21
WO2022033978A3 (en) 2022-04-14
JP2023537115A (ja) 2023-08-30
WO2022033978A2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
US20230099801A1 (en) Restoration of t cell activity via the cd39/cd73 axis
JP7530913B2 (ja) Cd73遮断抗体
EP3535298B1 (en) Antibodies to pd-1 and uses thereof
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
CN111372606B (zh) 增强atp释放作用
JP7065935B2 (ja) 抗ly6g6d抗体及び使用方法
JP2023036587A (ja) 癌を処置するための組成物及び方法
KR20200130403A (ko) 항-cd73 항체 및 그의 사용 방법
KR20160146747A (ko) 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
JP2020510435A (ja) 抗gitr抗体およびその使用方法
US20240270865A1 (en) Cancer treatment methods using anti-cd73 antibodies
CA3259402A1 (en) BINDING MOLECULES FOR CANCER TREATMENT
RU2819204C2 (ru) Антитела, блокирующие cd73
HK40060535B (en) Cd73 blocking antibodies
HK40060535A (zh) Cd73阻断抗体
HK40014070A (en) Antibodies to pd-1 and uses thereof
HK40014070B (en) Antibodies to pd-1 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination